Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

KROS Stock  USD 18.00  1.42  7.31%   
Slightly above 52% of Keros Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are impartial. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
OSAKA, Japan CAMBRIDGE, Mass., December 03, 2024--Takeda today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.

Read at finance.yahoo.com
Yahoo News
  

Keros Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Keros Therapeutics Fundamental Analysis

We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Keros Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Keros Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.

Peers

Keros Therapeutics Related Equities

EWTXEdgewise Therapeutics   18.36   
0%
100.0%
FENCFennec Pharmaceuticals   2.02   
0%
11.0%
MGTXMeiraGTx Holdings   1.91   
0%
10.0%
HRMYHarmony Biosciences   1.72   
0%
9.0%
MLYSMineralys Therapeutics,   1.56   
0%
8.0%
AVTEAerovate Therapeutics   1.19   
0%
6.0%
IDYAIdeaya Biosciences   1.07   
0%
5.0%
ERASErasca   0.38   
0%
2.0%
GLUEMonte Rosa   0.13   
1.0%
0%
REPLReplimune   0.56   
3.0%
0%
KZRKezar Life   0.91   
4.0%
0%
SNDXSyndax Pharmaceuticals   1.16   
6.0%
0%
BOLTBolt Biotherapeutics   1.89   
10.0%
0%
JANXJanux Therapeutics   3.17   
17.0%
0%
ANABAnaptysBio   3.96   
21.0%
0%
IPSCCentury Therapeutics   4.10   
22.0%
0%
SRZNSurrozen   4.80   
26.0%
0%
LRMRLarimar Therapeutics   10.56   
57.0%
0%

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.